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Abstract The human microbiota is paramount for normal host physiology. Altered host-microbiome 
interactions are part of the pathogenesis of numerous common ailments. Currently, much 
emphasis is placed on the involvement of the microbiome in the pathogenesis of type-2 diabetes 
mellitus (T2DM), impaired glucose tolerance, and other metabolic disorders (i.e. obesity). Several 
studies found highly significant correlations of specific intestinal bacteria with T2DM. A better 
understanding of the role of the microbiome in diabetes and its complications might provide new 
insights in the development of new therapeutic principles. 
Our pilot study investigates the microbiota patterns in Romanian type-2 diabetic patients with 
diabetic kidney disease. Fecal samples were collected from type 2-diabetic patients and healthy 
controls and further used for bacterial DNA isolation. Using 16 rDNA qRT-PCR, we analyzed 
phyla abundance (Bacteroidetes, Firmicutes) as well as the relative abundance of specific 
bacterial groups (Lactobacillus sp., Enterobacteriaceae, Ruminococus sp., Prevotella sp., 
Faecalibacterium sp., Clostridium coccoides, Clostridium leptum). Our study also investigates the 
diabetic fungal microbiome for the first time. Furthermore, we report significant correlations 
between the treatment regimen and microbiota composition in diabetic nephropathy. 
Keywords  type-2 diabetes, microbiota, microbiome, host-microbiome interactions, dysbiosis 
Highlights  This study investigates the changes present in the fungal microbiota of diabetic patients 
with diabetic kidney disease, and existing correlations between treatment regimens and 
microbiota patterns. 
 These preliminary results pave the way for additional studies on larger patient cohorts. 
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Introduction 
Diabetes is a public health problem affecting 
approximately 10% of adults worldwide (1). The 
International Diabetes Federation predicts that there will 
be 592 million diabetic cases with an additional 175 
million undiagnosed diabetic cases by 2035 (2). In 
Romania, 11.6% of the population aged between 20-79 
suffers from diabetes, thus placing our country on the 
second place in Europe in terms of diabetic prevalence 
(3). This chronic ailment is often complicated by an 
increased risk of heart disease, stroke and kidney failure 
(4). Diabetic kidney disease, classically defined by the 
presence of proteinuria (macroalbuminuria), is a common 
complication most likely to occur in patients with poor 
glycemic control, hypertension, glomerular hyperfiltration 
or genetic predisposition (5). 
Along this line of thinking, there is a growing public 
and scientific interest in identifying and modulating the 
key factors that govern the onset of diabetes and its 
complications. Factors such as rapid environmental 
changes and modern lifestyle are the major culprits for the 
alteration of the intestinal microbiota which controls the 
risk of developing metabolic dysfunction. The gut 
microbiota is also involved in the development of the 
immune system and multiple metabolic pathways. 
Therefore, disturbances in its composition and 
functionality induced by dietary changes will hinder the 
gut barrier function. A disrupted gut barrier permits 
passage of microorganisms, microbial products and 
foreign antigens into the mucosa subsequently leading to 
the immune system activation and secretion of 
inflammatory mediators. This low-grade chronic 
inflammation induced by a defective gut barrier further 
modifies host adiposity and insulin resistance (6). Several 
recent studies have reported changes in the gut microbiota 
of individuals at risk of developing diabetes as well as in 
already diagnosed patients (7). Even though there has 
been no clear microbiota pattern linked to diabetes so far, 
it was shown that diabetic individuals generally exhibit 
reduced bacterial diversity characterized by a reduction of 
butyrate-producing bacteria such as Faecalibacterium 
prausnitzii and Roseburia intestinalis along with an 
increase in opportunistic pathogens (pathobionts) (8). 
Within this context, our study investigates the 
microbiota signatures in Romanian patients with diabetic 
nephropathy and compares it with the microbiota patterns 
identified in other currently available studies. For the first 
time, our study investigates the fungal microbiota of 
diabetic patients. 
Materials and Methods 
Patients 
The study population (n=9) was represented by 
diabetic patients from “N. C. Paulescu” National Institute 
of Diabetes, Nutrition and Metabolic Diseases in 
Bucharest, Romania, and healthy volunteers. All 
participants received and signed the informed consent, 
and the Ethical Committee approved the study. All the 
enrolled T2D subjects were diagnosed based on the WHO 
criteria, namely: polyuria, polydipsia and polyphagia as 
well as one of the following: a random venous plasma 
glucose concentration ≥ 11.1 mmol/l or a fasting plasma 
glucose concentration ≥ 7.0 mmol/l (whole blood ≥ 6.1 
mmol/l) or two hour plasma glucose concentration ≥ 11.1 
mmol/l two hours after 75g anhydrous glucose in an oral 
glucose tolerance test (9). 
Microbiota analysis 
Stool samples were collected at home by the 
participants following a standardized procedure including 
antiseptic handling, collection in sterile containers and 
immediate freezing at −20°C. Fecal DNA was extracted 
using the AllPrep PowerViral DNA/RNA (Qiagen) 
according to the manufacturer’s instructions. Genomic 
DNA concentration was determined at a wavelength of 
260 nm using a NanoDrop (Thermo Scientific). For qPCR 
analysis, DNA samples were diluted in DNAse free water 
to a concentration of 3 ng/μl. RT-PCR measured the 
relative abundance of intestinal microorganisms in fecal 
DNA isolated from T2DM patients and healthy controls 
on a ViiA7© Fast Real-Time System.  
DNA samples were amplified using the bacterial or 
fungal group-specific primers at their specific annealing 
temperatures. Eubacteria primers were used to amplify a 
segment of the 16S rDNA in order to determine the total 
number of bacteria per sample. The primers used are 
listed in Table 1. Each PCR reaction included 200 nM of 
forward and reversed primer, 9 ng of DNA, and 2x SYBR 
Green Master Mix (Applied Biosystems). Samples 
without DNA template served as negative controls. 
Samples were incubated at 95ºC for 5 min, and then 
amplified through 45 cycles of 95ºC for 10 s, 60ºC for 30 
s, and 72ºC for 1 s. 
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Table 1. Primers used in this study 
Taxonomic 
target 
Primer sequence 
Eubacteria 
UniF340 ACT CCT ACG GGA GGC AGC AGT 
UniR514 ATT ACC GCG GCT GCT GGC 
Lactobacilli 
LabF362 ACG AGT AGG GAA ATC TTC CA 
LabR677 CAC CGC TAC ACA TGG AG 
Entero- 
bacteriaceae 
Uni515F GTG CCA GCM GCC GCG GTAA 
Ent826R GCC TCA AGG GCA CAA CCT CCA AG 
BPP 
Fwd GGTGTCGGCTTAAGTGCCAT 
Rev CGGACGTAAGGGCCGTGC 
F. prausnitzii 
Fwd CCCTTCAGTGCCGCAGT 
Rev GTCGCAGGATGTCAAGAC 
Bacteroidetes 
Bact934F GGAACATGTGGTTTAATTCGATGAT 
Bact1060R AGCTGACGACAACCATGCAG 
Firmicutes 
Firm934F GGAGCATGTGGTTTAATTCGAAGCA 
Firm 1060R AGCTGACGACAACCATGCAC 
Clostridium leptum 
Fwd GCACAAGCAGTGGAGT 
Rev CTTCCTCCGTTTTGTCAA 
Clostridium 
cocoides 
Fwd GAC GCC GCG TGA AGG A 
Rev AGC CCC AGC CTT TCA CAT C 
Ruminococcus 
Fwd ACTGAGAGGTTGAACGGCCA 
Rev CCTTTACACCCAGTAATTCCGGA 
Turicibacter 
Fwd CAGACGGGGACAACGATTGGA 
Rev TACGCATCGTCGCCTTGGGTA 
Fungal 18S 
Fwd ATTGGAGGGCAAGTCTGGTG 
Rev CCGATCCCTAGTCGGCATAG 
Saccharomyces 
Fwd AGGAGTGCGGTTCTTTG 
Rev TACTTACCGAGGCAAGCTACA 
Candida 
Fwd TTTATCAACTTGTCACACCAGA 
Rev ATCCCGCCTTACCACTACCG 
The statistical analysis 
The data in our study are presented as mean ± SEM 
and were graphed using the GraphPad Prism 5.0 software. 
Sample size (n) denotes biological replicates. Differences 
in microbial relative abundance were assessed using a 
non-parametric Mann-Whitney test. The *p < 0.05 was 
considered statistically significant. The statistically 
significant levels were *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
Results 
Our pilot study enrolled 9 T2DM patients with 
diabetic nephropathy and 5 healthy controls. Besides 
diabetic kidney disease, the enrolled T2DM patients 
also suffered from neuropathy (7 patients), 
retinopathy (7 patients), osteoporosis (2 patients), 
diabetic foot (1 patient), dyslipidemia (8 patients) and 
steatosis (6 patients) (Figure 1 A).  
No statistically significant difference was 
observed regarding the body mass index (BMI) 
between the two experimental groups (p=0.0790) 
(Figure 1 B). In our pilot analysis, we compared the 
fecal microbiota of patients with type-2 diabetes with 
that of healthy volunteers using qPCR of the 16S 
rRNA gene. qPCR analysis was done using SYBR 
Green primers recognizing different phyla such as 
Bacteroidetes and Firmicutes, but also bacterial 
families such as Lactobacillaceae and 
Enterobacteriaceae. Primers for the Universal 
Eubacteria 16S were used for normalization. 
 
 
Figure 1. Patient characteristics. A. Associated 
diabetic complications identified in the enrolled 
patients. B. Body mass index differences 
between healthy controls and T2DM patients 
(Student t-test, p=0.0790) 
The total amount of bacteria in the stool samples 
are represented as threshold cycle values (Ct) in 
Figure 2A. Both healthy controls and T2DM patients 
with diabetic nephropathy harbored similar levels of 
Eubacteria (Figure 2 A).  
The most common organisms in the human gut 
microbiota are members of the Gram-positive 
Firmicutes and the Gram-negative Bacteroidetes phyla, 
followed by several other phyla, including 
the Actinobacteria, usobacteria and Verrucomicrobia 
(10).  
The data from animal models and human studies 
have revealed differences in the two dominant 
bacterial phyla with a significant increase of 
Firmicutes and decrease of Bacteroidetes levels in 
obesity (11). Regardless their disease status, the 
subjects enrolled in our study had BMI values ranging 
from 20 to 38 (Figure 1B), and therefore, there is no 
surprise that we did not observe significant 
differences between Bacteroidetes and Firmicutes 
abundance (Figure 2 B-C), even though T2DM 
patients exhibited a tendency to harbor more 
Firmicutes (Figure 2 C). 
Gratiela P. Gradisteanu et al. 
 133 
 
Figure 2. Microbiota analysis in patients with T2DM 
patients with diabetic nephropathy. A. Total bacteria 
represented as Ct values obtained from qRT-PCR 
targeting the 16S rDNA of all Eubacteria. The 
abundance of the Bacteroidetes (B) and Firmicutes (C) 
phyla in the stool samples harvested from healthy 
individuals (Control) and patients with diabetic 
nephropathy (T2DM). 
The Bacteroidetes phyla range in relative abundance 
among individuals, but generally, make up half or more of 
the gut microbiome.  The three predominant Bacteroidetes 
genera of the human gastrointestinal tract are represented 
by Bacteroides, Prevotella, and Porphyromonas (BPP). In 
our analysis, no significant differences were observed in 
the BPP levels between T2DM patients and healthy 
controls (Figure 3 A).  
The strictly anaerobic Clostridium coccoides group 
constitutes 25% to 60% of the total microbiota and 
comprises a large number of species of genera such as 
Clostridium, Blautia, Anaerostipes, Ruminococcus, Dorea 
Eubacterium and Roseburia (12, 13). In our analysis, 
Clostridium coccoides’ relative abundance was similar 
between healthy controls and T2DM patients with 
diabetic nephropathy (Figure 3B). The qPCR results 
indicated that the amounts of Clostridium leptum tended 
to be higher in T2DM patients, compared to healthy 
controls (Figure 3 C). The Clostridium leptum group of 
bacteria (also called Clostridial cluster IV) is a dominant 
group of fecal bacteria in adult humans, representing 
around 16-25% of the fecal microbiota and it includes 
Faecalibacterium prausnitzii and certain species of 
Eubacterium and Ruminococcus (13).  
Following the same pattern, T2DM patients 
exhibited increased levels of Faecalibacterium 
prausnitzii and Ruminococcus. No statistically 
significant differences were observed between the two 
experimental groups regarding the Clostridium leptum-
Ruminococcus-Faecalibacterium prausnitzii levels, 
highlighting the need to increase the sample size in a 
subsequent study (Figure 3 D, E). The fecal 
microbiome of T2DM had significantly higher levels of 
Turicibacter sp. (*p= 0.0128) (Figure 3 F).  
Although the exact role of this butyrate-producing 
bacteria in the development of metabolic syndrome is not 
known, one study reported an increased abundance 
of Turicibacter in the gut of patients with rheumatoid 
arthritis, an immune-mediated disease (14). 
 
Figure 3. Microbiota patterns in patients with 
T2DM patients with diabetic nephropathy. 
Relative abundance of Bacteroides-Prevotella-
Porphyromonas (A), Clostridium coccoides (B), 
Clostridium leptum (C), Faecalibacterium 
prausnitzii (D), Ruminococcus (E) and 
Turicibacter (F) in stool samples harvested from 
healthy individuals (Control) and patients with 
diabetic nephropathy (T2DM). 
Interestingly though, T2DM patients harbored a 
microbiota enriched in Butyricicoccus spp. Butyricicoccus 
members are strictly anaerobic Clostridium cluster IV 
bacteria that produce high levels of butyrate (a short fatty 
chain of utmost importance for intestinal homeostasis) 
and are currently investigated as potential probiotics 
(Figure 4A). Under such circumstances, lactobacilli have 
also been widely characterized as potent probiotic strains 
in numerous studies. Nevertheless, we have tested the 
relative abundance of lactobacilli in T2DM patients and 
healthy controls, and we did not observe any differences 
(Figure 4B).  
Oxidative stress and inflammation, especially when 
accompanied by obesity, mutually potentiate each other 
and promote the onset of beta-pancreatic cell dysfunction, 
insulin resistance and T2DM vascular complications. In 
accordance with this, several studies have linked 
oxidative stress to dysbiosis (15). The intestinal tract 
harbors a radical oxygen gradient and hence microbes that 
reside in the colonic mucosa exhibit elevated oxygen 
tolerance and catalase expression compared to luminal or 
stool-associated bacteria (15). Moreover, inflammation 
also promotes an oxidative milieu characterized by the 
enrichment of aerotolerant phyla such as Proteobacteria 
and Actinobacteria. Gut inflammation was reported to be 
Microbiota signatures in Romanian type-2 diabetic patients 
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responsible for the production of terminal electron 
acceptors needed by facultative anaerobes such as 
Enterobacteriaceae further augmenting dysbiosis (16, 17). 
Specific taxonomic shifts have been linked to intestinal 
inflammation, including a relative increase in the 
abundance of Enterobacteriaceae, such as Escherichia 
coli and Fusobacterium. In our pilot study, the T2DM 
microbiota was characterized by significantly higher 
levels of Enterobacteriaceae (*p= 0.0238), hence 
suggesting a possible link between diabetes and intestinal 
inflammation (Figure 4 C). 
 
Figure 4. Relative abundance of Butyricicocus 
(A), Lactobacillus (B), and Enterobacteriaceae 
(C) in stool samples harvested from healthy 
individuals (Control) and patients with diabetic 
nephropathy (T2DM). 
For the first time, this study also investigates the 
differences in the fungal microbiome of diabetic patients 
with kidney disease. For this purpose, we quantified the total 
amount of fungal DNA in stool samples using universal 
primers for fungal 18S rDNA and the relative abundance of 
fungal populations such as Candida sp. and Saccharomyces 
sp. using specific primers (Figure 5 A-C). We observed no 
statistically significant differences regarding the total amount 
of fungal DNA sequences or Candida sp. levels. We did, 
however, find a tendency for higher levels of Saccharomyces 
sp. in T2DM patients but these findings need to be confirmed 
among a larger patient cohort. 
 
Figure 5. Fungal microbiome in diabetic nephropathy: 
total abundance of fungal 18SrDNA (expressed as Ct 
values), Candida sp. (B) and Saccharomyces sp. (C) 
abundance in the stool samples harvested from healthy 
individuals (Control) and patients with diabetic 
nephropathy (T2DM). 
Compelling recent data reveal the important role that 
medication has in triggering changes in the gut 
microbiota. For instance, the treatment with metformin 
alters the microbiome by promoting the growth of 
Akkermansia muciniphila, Lactobacillus sp., Escherichia 
spp, and by lowering the levels of Intestinibacter (18). 
Bearing this in mind, we tested whether treatment 
regimens impact microbiota signatures in diabetic 
nephropathy. Of all the T2DM patients tested, 6 patients 
(66.6%) received sevelamer carbonate, a phosphate 
binding drug prescribed to prevent hyperphosphatemia in 
patients with chronic renal failure.  Interestingly, the 
sevelamer carbonate treatment was significantly 
correlated with lower levels of both Enterobacteriaceae 
and Turicibacter (Figure 6 A, B).  
Importantly, the sevelamer carbonate treatment 
decreases levels of potentially pathogenic bacteria 
(Enterobacteriaceae), and these results need further 
investigation among a larger patient cohort. The other 
tested bacterial and fungal populations behaved similarly 
regardless of the sevelamer administration. 
 
Figure 6. The sevelamer carbonate treatment 
triggers changes in microbiota composition: 
Turicibacter sp. (A) and Enterobacteriaceae (B) 
are relatively abundant in the stool samples 
harvested from healthy individuals (Control) and 
patients with diabetic nephropathy (T2DM). 
Discussions 
Human microbiome profiles depend on diet, ethnic 
origin, geographic region and age. However, despite these 
variables, the microbiome of T2DM patients was 
suggested to have some particular features. The 
microbiota of T2DM patients has low levels of mucin 
degrading bacteria such as Akkermansia sp. and 
Prevotella sp. (19) and also butyrate-producing 
microorganisms, such as Faecalibacterium prausnitzii, 
Gratiela P. Gradisteanu et al. 
 135 
Clostridium sp., Roseburia intestinalis, Eubacterium 
rectale and Faecalibacterium sp. (20). The human T2DM 
intestinal microbiota was shown to be inhabited by 
opportunistic pathogens including the sulphate-reducing 
genus Desulfovibrio, Escherichia coli and 
Bacteroidaceae. A study performed on Chinese T2DM 
patients revealed an increase in Escherichia coli. 
Furthermore, a Danish study reported elevated 
Proteobacteria in T2DM (21). A study performed on 
Romanian subjects revealed that the most common 
aerobic/facultative anaerobic species isolated from the 
stool cultures of 100 patients with dyslipidemia, diabetes 
and obesity were Gram-negative bacteria (22). Our results 
are partially in accordance with these studies. Similar to 
the study by Larsen et al., we showed that T2DM 
microbiota is enriched in Enterobacteriaceae.  
In contrast with previously published studies, we 
observed that T2DM patients harbored a microbiota 
slightly enriched in butyrate-producing microorganisms, 
but the difference was not statistically significant. To 
address this question, we need to perform further studies 
on a larger patient cohort using next-generation 
sequencing techniques to ascertain better microbiome 
features in T2DM associated with nephropathy. Bacterial 
counts of the L. acidophilus, L. plantarum and L. reuteri 
subgroups of Lactobacillus sp. were significantly lower 
among Romanian patients with T2DM and obesity 
compared to healthy controls (23). In our study group, no 
differences were seen in case of lactobacilli abundance in 
the stool samples harvested from T2DM patients. 
However, one must consider that the levels of lactobacilli 
inhabiting the microbiota are highly dependent on the 
host’s diet. 
Conclusions 
Herein, we present a pilot study analyzing the 
microbiome patterns associated with diabetic nephropathy 
in Romanian patients. For the first time, we investigate 
the changes present in the fungal microbiota of diabetic 
patients with diabetic kidney disease. Besides, we 
describe significant correlations between treatment 
regimens and microbiota patterns. These preliminary 
results pave the way for additional studies on larger 
patient cohorts. 
Acknowledgement 
All authors had an equal scientific contribution and 
shared the first authorship. 
 
Conflict of interest disclosure 
There are no known conflicts of interest in the 
publication of this article. The manuscript was read and 
approved by all authors. 
Compliance with ethical standards 
Any aspect of the work covered in this manuscript has 
been conducted with the ethical approval of all relevant 
bodies and that such approvals are acknowledged within 
the manuscript. 
References 
1. Astrup AFN. Redefining type 2 diabetes: ‘diabesity’ 
or ‘obesity dependent diabetes mellitus’? Obes Rev. 
2001; 1(2): 57–9.  
2. Ayadurai S, Hattingh HL, Tee LB, et al. A narrative 
review of diabetes intervention studies to explore 
diabetes care opportunities for pharmacists.  
J Diabetes Res. 2016; 2016: 5897452. DOI: 
10.1155/2016/5897452    
3. Mota M, Popa SG, Mota E, Mitrea A, Catrinoiu D, et 
al. Prevalence of diabetes mellitus and prediabetes in 
the adult Romanian population: PREDATORR study. 
J Diabetes. 2016; 8(3): 336–44. DOI: 10.1111/1753-
0407.12297 
4. Rusu A, Bala CG, Craciun AE, et al. HbA1c levels are 
associated with severity of hypoxemia and not with 
apnea hypopnea index in patients with type 2 diabetes: 
Results from a cross-sectional study. Journal of 
Diabetes. 2017; 9(6): 555-61.  
5. Bala C, Craciun AE, Hancu N. Updating the concept 
of metabolically healthy obesity. Acta 
Endocrinologica-Bucharest. 2016; 12(2): 197-205.    
6. Musso G, Gambino R, Cassader M. Obesity, diabetes, 
and gut microbiota: The hygiene hypothesis 
expanded? Diabetes Care. 2010; 33(10): 2277–84. 
DOI: 10.2337/dc10-0556 
7. Larsen N, Vogensen FK, Van Den Berg FWJ, Nielsen 
DS, Andreasen AS, Pedersen BK, et al. Gut 
microbiota in human adults with type 2 diabetes 
differs from non-diabetic adults. PLoS One. 2010; 
5(2): e9085. DOI: 10.1371/journal.pone.0009085  
8. Junjie Qin, Yingrui Li, Zhiming Cai, Shenghui Li, 
Jianfeng Zhu, Fan Zhang, Suisha Liang, Wenwei 
Zhang, Yuanlin Guan, Dongqian Shen, Yangqing 
Peng, Dongya Zhang, Zhuye Jie, Wenxian Wu, 
Youwen Qin, Wenbin Xue, Junhua Li, Lingchuan 
Han, Donghui Lu, Peixian W SZ. A metagenome-
wide association study of gut microbiota in type 2 
Microbiota signatures in Romanian type-2 diabetic patients 
 136 
diabetes. Nature. 2012; 490(7418): 55–60. DOI: 
10.1038/nature11450 
9. World Health Organization. Global Report on 
Diabetes. Isbn. 2016; 978: 88.  
10. Eckburg PB, Bik EM, Bernstein CN, Purdom E, 
Dethlefsen L, Sargent M et al. Diversity of the human 
intestinal microbial flora. Science. 2005; 308(5728): 
1635-8. DOI: 10.1126/science.1110591  
11. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, 
Knight RD, Gordon JI. Obesity alters gut microbial 
ecology. Proc Natl Acad Sci U S A. 2005; 102(31): 
11070–75. DOI: 10.1073/pnas.0504978102 
12. Hayashi H, Sakamoto M BY. Phylogenetic analysis of 
the human gut microbiota using 16S rDNA clone 
libraries and strictly anaerobic culture-based methods. 
Microbiol Immunol. 2002; 46(8): 535–48.  
13. Matsuki T, Watanabe K, Fujimoto J, Takada T TR. 
Use of 16S rRNA gene-targeted group-specific 
primers for real-time PCR analysis of predominant 
bacteria in human feces. Appl Env Microbiol.  
2004; 70: 7220–8. DOI: 10.1128/AEM.70.12.7220-
7228.2004  
14. Forbes J D, Van Domselaar G, Bernstein CN. The Gut 
Microbiota in Immune-Mediated Inflammatory 
Diseases. Front Microbiol. 2016; 7: 1081. DOI: 
10.3389/fmicb.2016.01081 
15. Albenberg L, Esipova TV, Judge CP, Bittinger K, 
Chen J, Laughlin A, et al. Correlation between 
intraluminal oxygen gradient and radial partitioning of 
intestinal microbiota. Gastroenterology 2014; 147(5): 
1055–1063. DOI: 10.1053/j.gastro.2014.07.020 
16. Lopez CA, Miller BM, Rivera-Chavez F, et al. 
Virulence factors enhance Citrobacter rodentium 
expansion through aerobic respiration. Science. 2016; 
353(6305): 1249–1253. DOI: 10.1126/science. 
aag3042  
17. Winter SE, Lopez CA, Bäumler AJ. The dynamics of 
gut-associated microbial communities during 
inflammation. EMBO Rep. 2013; 14(4): 319–27. DOI: 
10.1038/embor.2013.27 
18. Forslund K, Hildebrand F, Nielsen T, Falony G, Le 
Chatelier E, Sunagawa S, et al. Disentangling type 2 
diabetes and metformin treatment signatures in the 
human gut microbiota. Nature. 2015; 528(7581): 262–
6. DOI: 10.1038/nature15766 
19. Brown CT, Davis-Richardson AG, Giongo A, Gano 
KA, Crabb DB, Mukherjee N, Casella G, Drew JC, 
Ilonen J, Knip M, et al. Gut microbiome 
metagenomics analysis suggests a functional model 
for the development of autoimmunity for type 1 
diabetes. PLoS One. 2011; (6): e25792. DOI: 
10.1371/journal.pone.0025792 
20. Paunica M, Gheorghiu R, Curaj A, Holeab C. 
Foresight for restructuring R&D systems. Amfiteatru 
economic 2009; 11(25): 201-210. 
21. Larsen N, Vogensen FK, van den Berg FW, Nielsen 
DS, Andreasen AS, Pedersen BK, Al-Soud WA, 
Sørensen SJ, Hansen LH JM. Gut microbiota in 
human adults with type 2 diabetes differs from non-
diabetic adults. PLoS One. 2010; 5(2): e9085. DOI: 
10.1371/journal.pone.0009085 
22. Chelariu M, Grosu M, Gheorghe I, Gradisteanu G, 
Picu A, Petcu L, et al. Host metabolic syndrome can 
disrupt the intestinal microbiota and promote the 
acquisition of resistance and virulence genes in 
Enterobacteriaceae stains. Rom Biotechnol Lett. 2017; 
22(3): 12643–50. 
23. Suceveanu AI, Pantea Stoian A, Parepa RI, Voinea C, 
Hainarosie R, Manuc D, et al. Gut microbiota patterns 
in obese and type 2 diabetes. (T2D) patients from 
Romanian black sea coast region. Rev Chim. 2018; 69: 
2260–7. 
 
